Portfolio company
Basking Biosciences
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops reversible therapies targeting von Willebrand Factor for patients with acute thrombotic conditions, such as strokes.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Acticor Biotech
The company develops glenzocimab, a therapeutic antibody fragment for treating patients with acute ischemic stroke and other thrombotic diseases.
TargED Biopharmaceuticals
The company develops targeted biological drugs to treat thrombotic diseases such as acute ischaemic stroke and immune-mediated thrombotic thrombocytopenic purpura for healthcare providers.
Therini Bio
The company develops fibrin-targeting monoclonal antibodies to treat patients with neurodegenerative and retinal diseases caused by vascular-mediated inflammation.
Biomedical Solutions
This company develops endovascular thrombus removal devices for healthcare providers to treat patients suffering from acute ischemic stroke.
Julier Medical
This company develops an expandable endovascular catheter platform and mechanical thrombectomy devices for clinicians to treat patients experiencing acute ischemic strokes.
Aptatargets
The company develops aptamer-based therapeutic drugs for patients with acute ischemic stroke and other inflammatory or cardiovascular diseases.
Imperative Care
This company develops thrombectomy systems and digital health tools to treat patients suffering from strokes and other vascular diseases.
VarmX
This biotech company develops recombinant blood clotting factors to treat patients with severe bleeding or requiring urgent surgery while taking oral anticoagulants.